Educational content only. Not medical advice. Consult a qualified physician.
Kisspeptin peptide
Sexual HealthInvestigational. Active area of clinical research at institutions including Imperial College London. Not FDA-approved for any therapeutic indication.

Kisspeptin

Kisspeptin is a neuropeptide encoded by the KISS1 gene that plays a central role in initiating puberty and regulating the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates the release of GnRH from the hypothalamus, which in turn triggers LH and FSH secretion. Research has expanded beyond reproduction to include studies on sexual arousal, mood, and metabolic function.
Reported Benefits

Potential Benefits

  • Research confirms kisspeptin as a key regulator of reproductive hormone cascades
  • Clinical studies suggest it can stimulate LH and FSH release in both men and women
  • Neuroimaging studies indicate potential to enhance brain processing of sexual and emotional stimuli
  • May have applications in diagnosing and treating reproductive disorders
  • Research suggests potential metabolic regulatory roles
Research Dosing

Recommended Starting Dose

1 nmol/kg intravenously (research setting); not established for clinical outpatient use

Based on published research protocols. Not a prescription.

Dosing Protocol

In research settings, kisspeptin-54 has been administered as single IV bolus injections (1-10 nmol/kg) or as continuous infusions. No established outpatient clinical protocol exists. The short half-life necessitates IV administration or development of longer-acting analogs.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Hormonal responses (LH surge) occur within minutes to hours of IV administration. This is primarily a research tool at this stage.

Regulatory

Research Status

Investigational. Active area of clinical research at institutions including Imperial College London. Not FDA-approved for any therapeutic indication.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Research compound with limited clinical safety data for therapeutic use
  • Injection site reactions
  • Potential headache and flushing
  • Effects on reproductive hormones require careful monitoring
  • Short half-life (minutes) limits practical therapeutic application
  • Long-term effects of exogenous administration are unknown
Related Research

More in Sexual Health

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.